

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (rapid review of TA711) [ID4013]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
N/A (rapid review)

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
The company raised a potential equalities issue stating that the administration of the Psoriasis Area Severity Index (PASI) instrument may create a barrier to access if a recommendation was made requiring clinicians to judge comorbid skin symptoms. This is because it obtained clinical expert advice that most rheumatologists do not measure PASI in routine clinics. Whilst the updated recommendation following the rapid review does not involve the administration of the PASI instrument to determine treatment suitability, the committee was satisfied that administration of the PASI instrument should be routine practice given the British Society for Rheumatology guidelines which recommend that “a PASI score should be completed for patients with significant skin psoriasis in collaboration with a

dermatologist”, were published in 2012. The committee was satisfied that there were no equalities concerns.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality?

No

7. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.17

Furthermore, in TA711 the committee noted that other appraisals in the same disease area had included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC. This is reflected in recommendations 1.3 and 1.4.

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 13 June 2022